Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on BioDelivery (BDSI) today and set a price target of $5. The company’s shares closed yesterday at $4.49, close to its 52-week high of $4.74.
Folkes wrote:
“We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.5% and a 42.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, ANI Pharmaceuticals Inc, and Emergent Biosolutions.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioDelivery with a $5 average price target, which is an 11.4% upside from current levels. In a report issued on January 31, Janney Montgomery also initiated coverage with a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
Based on BioDelivery’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.38 million. In comparison, last year the company had a GAAP net loss of $16.21 million.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.
